Testing probiotic strain Escherichia coli Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities.
A high carriage rate of multidrug-resistant Escherichia coli (MDREC) was observed in elderly residents in long-term care facilities. A double-blinded, placebo-controlled trial was carried out to determine whether the probiotic product E. coli strain Nissle 1917 (Mutaflor) would compete with MDREC in the bowel and thereby reduce the prevalence of the multiresistant bacteria in faeces and urine. Sixty-nine patients excreting norfloxacin-resistant E. coli were randomized to probiotic or placebo groups and administered capsules twice daily. The daily dose of probiotic was 5×10(9)-5×10(10) bacteria. Faecal and urine samples were cultured at baseline and during and after the treatment period. A reduction in baseline carriage was not influenced by probiotic administration. The probiotic strain was detected in faecal specimens collected during the treatment period of only two out of 12 probiotic group subjects that were tested. Genotyping of norfloxacin-resistant E. coli isolates showed that 32 strains were prevalent among the patients. Thus, E. coli Nissle 1917 does not have the capacity to compete effectively with MDREC in the bowel of elderly patients.
Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Gerald W
GW
Tannock
Department of Medical and Surgical Sciences, University of Otago, Dunedin, New Zealand.
Ing Soo
IS
Tiong
Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.
Patricia
P
Priest
Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Karen
K
Munro
Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Corinda
C
Taylor
Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Alice
A
Richardson
Department of Medical and Surgical Sciences, University of Otago, Dunedin, New Zealand.
Michael
M
Schultz
D000368:Aged; D000369:Aged, 80 and over; D000898:Antibiosis; D002353:Carrier State / Q000382:microbiology*; D004311:Double-Blind Method; D024901:Drug Resistance, Multiple, Bacterial; D004926:Escherichia coli / Q000187:drug effects* / Q000502:physiology*; D004927:Escherichia coli Infections / Q000382:microbiology*; D005243:Feces / Q000382:microbiology; D006801:Humans; D008134:Long-Term Care; D010919:Placebos / Q000008:administration & dosage; D019936:Probiotics / Q000008:administration & dosage*; D014556:Urine / Q000382:microbiology
D010919:Placebos